FDMT

NASD 4D Molecular Therapeutics, Inc.
Oct 12, 2026 · 9:54 PM ET EOD Market Closed

$13.00 ↑ +0.00 (+0.00%) Trading Up from the previous close of $13.00, $0.47 below the day’s high of $13.47

YTD change
+73.33%
vs 20-day SMA
-7.58%
vs 200-day SMA
+23.46%

Price ranges

Previous day
$12.55 $13.85
open $12.70 close $13.33
+$0.63 (+4.96%)
Today
$12.86 $13.47
open $13.18 now $13.00
-$0.18 (-1.37%)
Past week
$12.12 $13.86
from $13.67 now $13.00
-$0.67 (-4.90%)
Past month
$12.12 $16.23
from $13.17 now $13.00
-$0.17 (-1.29%)
This year
$6.96 $16.93
from $7.50 now $13.00
+$5.50 (+73.33%)

Price & Performance

+2.96 (+29.48%) / 6M

$7.69$10.94$14.19$17.43Apr 13Jul 14Oct 12

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good
  • The stock is 55.1% away from all-time highs of $28.93
  • FDMT is up 73% since the beginning of the year
  • FDMT is up 46% over the past 12 months
  • FDMT is down 1% over the past 1 month

FDMT reads not so good: price sits above one of the two key moving averages, the 12-month move is +34.4%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.98
Earnings momentum +3.3% Quarterly EPS growth
Quarterly change +3.3%

Valuation

P/E ratio N/A
Enterprise value $126.4M
Beta 3.36

Balance sheet & scale

IncomeN/A
Revenue$33.0K
Cash$293.2M
Debt$23.1K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $938.3M

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $417.57 +0.65%
MRNA Moderna, Inc. $213.74 -5.00%
RVMD Revolution Medicines, Inc. $193.95 +2.21%
ROIV Roivant Sciences Ltd. $34.59 -2.40%
BNTX BioNTech SE Sponsored ADR $95.84 -1.16%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.